Publication of List of Manufacturers Revoked from Licensing for the Manufacture of Therapeutic Goods

Overview

The Therapeutic Goods Act 1989 was enacted by the Parliament of Australia to regulate the provision and distribution of therapeutic goods, ensuring they are safe and of high quality. This legislation addresses the critical need for stringent oversight of therapeutic products, including medicines, medical devices, and biologicals, to protect public health. The Act provides the legal framework for the Therapeutic Goods Administration (TGA) to license manufacturers, oversee manufacturing practices, and take regulatory action as necessary. The policy objective of the Act is to safeguard the health and safety of Australians by ensuring that therapeutic goods are of acceptable quality, efficacy, and safety. In accordance with the Act, the Delegate of the Secretary of the Department of Health, Therapeutic Goods Administration, has the authority to revoke licenses for the manufacture of therapeutic goods under specific circumstances, such as at the request of the manufacturer, to maintain regulatory compliance and public safety standards.

Scope and Application

The Therapeutic Goods Act 1989 governs the regulation of therapeutic goods in Australia, ensuring their quality, safety, and efficacy. The Act applies to persons and entities involved in the manufacture, importation, supply, or advertisement of therapeutic goods, including medicines, medical devices, and blood products. It encompasses a wide range of industries, such as pharmaceuticals, biotechnology, and healthcare. The Act's jurisdictional reach is national, with the Therapeutic Goods Administration (TGA) being the federal body responsible for its enforcement. The revocation of a licence to manufacture therapeutic goods, as indicated in the gazette, signifies the TGA's action to withdraw approval from entities that no longer meet the regulatory standards, at the request of the manufacturer themselves. The Act allows for the creation of subordinate instruments to extend or restrict its application, although the gazette in question does not detail any specific exclusions, exemptions, or thresholds.

Key Provisions

Under section 41(1)(d) of the Therapeutic Goods Act 1989, the Therapeutic Goods Administration (TGA) has the authority to revoke a licence to manufacture therapeutic goods. The notice published by David Rowbury, acting as a delegate for the Secretary of the Department of Health, details the revocation of licences held by three entities at their own request. Specifically, the licence of Verigen Australia Pty Ltd, located at 26 Harris Road, Malaga, WA, 6090, bearing the number MI-2010-LI-09146-3, has been revoked. Similarly, the licence of Boehringer Ingelheim Pty Ltd, situated at Level 1, 78 Waterloo Road, North Ryde, NSW, 2113, with the number MI-2013-LI-06919-1, has also been revoked. Lastly, the licence of the Pharmaceutical Testing Facility PTF Department of Microbiology, PathWest Laboratory Medicine WA, located at Level 3, Hay Street Building, Princess Margaret Hospital, Roberts Road, Subiaco, WA, 6008, with the number MI-14122004-LI-000307-1, has been revoked as well. The obligations and requirements imposed by the Therapeutic Goods Act 1989 on the entities whose licences have been revoked are primarily concerned with the cessation of manufacturing activities and compliance with the Act’s provisions. The revocation notice signifies that these entities are no longer authorised to manufacture therapeutic goods and must cease any such activities immediately. They must also ensure that all goods produced under their previous licences are handled in compliance with the Act, including proper disposal, recall, or other necessary actions to prevent any harm to the public. Additionally, the entities must notify the TGA of any remaining stock and cooperate in any required investigations or audits. In terms of legal consequences for breaches of the Therapeutic Goods Act 1989, the Act provides for both civil and criminal penalties. Offences under the Act can lead to fines and imprisonment. For instance, section 23 of the Act stipulates that a person who contravenes certain provisions can be fined up to $220,000 for a corporation and up to $44,000 for an individual. Furthermore, section 24 imposes penalties that can lead to imprisonment for up to five years for serious offences, such as the manufacturing of therapeutic goods without a valid licence. It is crucial for the entities mentioned to adhere strictly to the Act to avoid these severe penalties.